CA2284170C - Identification d'agents utiles dans le traitement de la maladie d'alzheimer - Google Patents

Identification d'agents utiles dans le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2284170C
CA2284170C CA002284170A CA2284170A CA2284170C CA 2284170 C CA2284170 C CA 2284170C CA 002284170 A CA002284170 A CA 002284170A CA 2284170 A CA2284170 A CA 2284170A CA 2284170 C CA2284170 C CA 2284170C
Authority
CA
Canada
Prior art keywords
sample
metal
sds
chelator
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002284170A
Other languages
English (en)
Other versions
CA2284170A1 (fr
Inventor
Ashley I. Bush
Xudong Huang
Craig S. Atwood
Rudolph E. Tanzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CA2284170A1 publication Critical patent/CA2284170A1/fr
Application granted granted Critical
Publication of CA2284170C publication Critical patent/CA2284170C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Cette invention a pour objet l'identification d'agents pharmacologiques destinés à être utilisés dans le traitement de la maladie d'Alzheimer et des états pathologiques associés. Sont également présentés des procédés et des compositions permettant de traiter des états pathologiques provoqués par l'amylose, la formation d'espèces réactives d'oxygène (EOR) induite par des peptides A beta , ou bien les deux, comme la maladie d'Alzheimer.
CA002284170A 1997-03-11 1998-03-11 Identification d'agents utiles dans le traitement de la maladie d'alzheimer Expired - Fee Related CA2284170C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81612297A 1997-03-11 1997-03-11
US08/816,122 1997-03-11
PCT/US1998/004683 WO1998040071A1 (fr) 1997-03-11 1998-03-11 Identification d'agents utiles dans le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
CA2284170A1 CA2284170A1 (fr) 1998-09-17
CA2284170C true CA2284170C (fr) 2008-12-02

Family

ID=25219748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284170A Expired - Fee Related CA2284170C (fr) 1997-03-11 1998-03-11 Identification d'agents utiles dans le traitement de la maladie d'alzheimer

Country Status (5)

Country Link
EP (1) EP1007048A4 (fr)
JP (1) JP2001514661A (fr)
AU (1) AU748768B2 (fr)
CA (1) CA2284170C (fr)
WO (1) WO1998040071A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
EA002526B1 (ru) 1997-08-21 2002-06-27 П.Н.Геролиматос С.А. Применение фанхинона для лечения болезни альцгеймера
WO1999018432A1 (fr) 1997-10-06 1999-04-15 The General Hospital Corporation Techniques de criblage de medicaments permettant de predire la dyskinesie tardive
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) * 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
CN1324234A (zh) 1998-09-25 2001-11-28 格利科克斯有限公司 果糖胺氧化酶,拮抗剂和抑制剂
WO2000040244A1 (fr) 1999-01-07 2000-07-13 P.N. Gerolymatos S.A. Utilisation de phanquinone pour le traitement ou la prevention des troubles mnesiques
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
EP1571158B1 (fr) * 1999-08-04 2009-10-14 University Of Southern California Assemblage de protéine amyloide beta globulaire et ses utilisations
AU2001239544A1 (en) * 2000-03-22 2001-10-03 Bf Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
AU2002351880B2 (en) * 2001-12-27 2007-08-30 Neuroscientific Biopharmaceuticals Pty Ltd Screening methods and the use of agents identified using the same
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
DK2500018T3 (en) 2002-03-08 2017-10-02 Philera New Zealand Ltd Prevention and / or treatment of cardiovascular disease and / or associated heart failure
CA2496411A1 (fr) 2002-08-20 2004-03-04 Protemix Corporation Limited Formes posologiques et traitements s'y rapportant
EP1606292A2 (fr) * 2003-03-21 2005-12-21 Palumed SA Derives polycycliques azotes utilises comme chelateurs d'ions metalliques et leurs applications
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体
US20050159364A1 (en) * 2003-12-19 2005-07-21 Cooper Garth J. Copper antagonist compounds
EP1778618B1 (fr) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthese de triethylenetetramines
BRPI0514052A (pt) 2004-08-03 2008-05-27 Transtech Pharma Inc proteìnas de fusão rage e métodos de utilização
NZ571692A (en) 2006-05-05 2012-01-12 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
BRPI0813452A2 (pt) 2007-06-14 2017-05-23 Galactica Pharmaceuticals Inc protéinas de fusão rage.
JP5684578B2 (ja) * 2008-03-03 2015-03-11 エヌエーディー ライフ プロプライエタリー リミテッド リスベラトロールの医薬製剤、および細胞障害を治療するためのその使用方法
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2018236221A2 (fr) * 2017-06-03 2018-12-27 Can Holding B.V. Dissolution de dépôt de peptide neurodégénératif
KR102048846B1 (ko) * 2017-11-20 2019-11-27 한국생명공학연구원 혈관 질환 치료제 및 이의 스크리닝 방법
JPWO2021015300A1 (fr) * 2019-07-25 2021-01-28

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5705401A (en) * 1991-11-12 1998-01-06 The University Of Melbourne Method of assaying for alzheimer's disease
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
JPH07149668A (ja) * 1993-11-30 1995-06-13 Kanegafuchi Chem Ind Co Ltd アミロイド沈着検出用物質
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
CA2214247C (fr) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
EP1006798A4 (fr) * 1996-09-05 2003-03-05 Massachusetts Inst Technology Compositions et procedes de traitement de troubles neurologiques et de maladies neurodegeneratives

Also Published As

Publication number Publication date
JP2001514661A (ja) 2001-09-11
AU748768B2 (en) 2002-06-13
EP1007048A1 (fr) 2000-06-14
CA2284170A1 (fr) 1998-09-17
WO1998040071A1 (fr) 1998-09-17
AU6548498A (en) 1998-09-29
EP1007048A4 (fr) 2004-09-22

Similar Documents

Publication Publication Date Title
CA2284170C (fr) Identification d'agents utiles dans le traitement de la maladie d'alzheimer
US6323218B1 (en) Agents for use in the treatment of Alzheimer's disease
WO1998040071A9 (fr) Identification d'agents utiles dans le traitement de la maladie d'alzheimer
Atwood et al. Dramatic aggregation of Alzheimer Aβ by Cu (II) is induced by conditions representing physiological acidosis
McLachlan Aluminium and the risk for Alzheimer's disease
Bush Metal complexing agents as therapies for Alzheimer’s disease
Atwood et al. Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar‐affinity copper binding site on amyloid β1‐42
Hare et al. A delicate balance: Iron metabolism and diseases of the brain
Suzuki et al. Inhibitory effect of copper (II) on zinc (II)-induced aggregation of amyloid β-peptide
PL188838B1 (pl) Zastosowanie kliochinolu do wytwarzania środka farmaceutycznego i środek farmaceutyczny
US7045531B1 (en) Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US20050112543A1 (en) Method of screening for drugs useful in treating Alzheimer's disease
McLachlan et al. Alzheimer's disease and other aluminum-associated health conditions
US6638711B1 (en) Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
CA2379858C (fr) Inhibiteurs du peptide amyloide-beta
CA2601285A1 (fr) Agents utilises pour traiter la maladie d'alzheimer
Curtain et al. Aβ Metallobiology and the Development of Novel Metal-Protein Attenuating Compounds (MPACs) for Alzheimer's Disease
Savory et al. Aluminum
Summers 8-Hydroxyquinoline Copper Complexes in the Treatment of Neurodegenerative Disease
White et al. The Metallobiology of Alzheimer's Disease: From Bench to Clinic.
JP2004506915A (ja) 白内障を阻害又は促進する物質を同定する方法及びその使用
AU780380C (en) Beta-amyloid peptide inhibitors
Ha Template-directed deposition of amyloid

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed